Comparative Pharmacology
Head-to-head clinical analysis: TIROSINT versus UNITHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIROSINT versus UNITHROID.
TIROSINT vs UNITHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirosint is a synthetic form of levothyroxine (T4), which is converted to triiodothyronine (T3) in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription to increase metabolic rate, protein synthesis, and oxygen consumption.
Synthetic T4 (levothyroxine) is converted to T3, which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate.
Initial dose 1.6 mcg/kg orally once daily, adjusted based on TSH levels. Typical maintenance dose 50-200 mcg/day.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 4-6 weeks based on TSH; typical maintenance: 75-150 mcg orally once daily; maximum dose up to 300 mcg daily in severe hypothyroidism.
None Documented
None Documented
Terminal half-life approximately 7 days in euthyroid individuals; prolonged in hypothyroidism (up to 9-10 days) and shortened in hyperthyroidism (3-4 days). Clinical context: steady-state reached in 4-6 weeks; dosage adjustments require 6-8 weeks for full effect.
6-7 days for L-thyroxine (T4) in euthyroid patients; prolonged to 9-10 days in hypothyroidism, shortened to 3-4 days in hyperthyroidism. Clinical context: once-daily dosing achieves steady state in 6-8 weeks.
Renal (approximately 30-40% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates); fecal (approximately 20-30% via bile); total clearance is low (~0.05 L/hr/kg).
Renal (approx. 20-40% as unchanged drug and glucuronide conjugates); fecal (minor, via bile).
Category C
Category C
Thyroid Hormone
Thyroid Hormone